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Abstract
Background. Taking into consideration the aging of HIV infected individuals, changes in the metabolism aggra-
vated by the antiretroviral therapy significantly impact their health. Mechanisms responsible for lipodystrophy, 
dyslipidemia and insulin resistance (IR) occurrence have not been completely understood. Only recently, the free 
fatty acids (FFAs) metabolic turnover has become considered to be the independent risk factor for cardiovascular 
complications.
Material and Methods. We designed the follow-up study in which patients were recruited before the introduc-
tion of ARV therapy and then observed up to 1 year. The impact of ARV therapy on the development of meta-
bolic complications, inflammation markers and changes in adipokines secretion was investigated. The fasting and 
postprandial responses of FFAs, triglycerides (TG), glucose, insulin and glucose-dependent insulinotropic peptide 
(GIP) were measured. Changes in body composition were followed by impedance and a CT scan of adipose tissue 
volume of the abdomen and thighs. 
Results. Significant impact of ARV therapy on metabolic disturbances was reported. Not only fasting, but also 
postprandial levels of FFAs and TG were found to increase during the follow up. 
Conclusions. The increased concentration of FFAs is suggested to be the triggering event in the development of 
hypertriglyceridemia and insulin resistance during ARV therapy. Changes in postprandial FFAs and TG during the 
follow up indicate the increasing risk of cardiovascular diseases. We conclude that modern ARV therapy during the 
period of 12 months does not induce changes in the fat distribution, although increased limb fat correlated with 
higher plasma leptin level, which may be the marker of increased risk of metabolic driven cardiovascular complica-
tions (Adv Clin Exp Med 2014, 23, 4, 539–549).
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Nowadays, HIV infection is considered a chronic 
condition, and therapy with ARV drugs significantly 
decreased the number of HIV related morbidity and 
mortality [1]. As the population of HIV infected pa-
tients is aging, we face new problems connected with 
increasing risk of metabolic and cardiovascular diseas-
es, which can have a significant impact on the quality 
of patients’ lives and can also decrease survival. 
The pathogenesis of the above complications 
in HIV infected population is complex and not 
completely explored [2]. There is evidence that 
therapy with ARV drugs, especially nucleoside re-
verse transcriptase inhibitors (NRTIs) and prote-
ase inhibitors (PIs), is associated with side effects 
such as lipodystrophy, hyperlipidemia and insulin 
resistance [3]. It is suggested that HIV infection by 
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itself can induce changes which are promote the 
development of metabolic disturbances [2, 4]. It 
has been documented that interrupting ARV ther-
apy, and in consequence uncontrolled HIV repli-
cation, may further increase the risk of all-causes 
mortality by raising IL-6 and D-dimers level [5]. 
Also, the SMART trial found a raised risk of car-
diovascular diseases in patients undergoing inter-
mittent therapy, although the reasons of this re-
main unclear [6]. 
As variable changes in lipid profile were re-
ported in ARV treated patients, little is known 
about the effect of HIV infection and ARV thera-
py on postprandial lipemia, which is considered to 
be an emerging cardiovascular diseases risk factor 
[7]. Insulin resistance is an element of metabolic 
disturbances which occur in HIV infected people 
[8]. The mechanism of insulin resistance is in part 
due to the disturbed lipid/FFAs metabolism and 
inflammation, which can promote lipotoxicity [8]. 
The postprandial, protective for beta-cells, incre-
tin response to oral nutrients have also been poorly 
followed in the development of impaired glucose 
tolerance in the ARV treated patients. To investi-
gate the pathogenesis of the above complications, 
we designed the follow up study in which HIV pa-
tients were recruited before the introduction of 
ARV therapy and then followed up to 1 year. The 
aim of the presented study was to assess the impact 
of ARV therapy on the development of metabolic 
complications, inflammation markers (TNFα, IL-
6,), as well as changes in the endocrine function of 
the adipose tissue connected with secretions of se-
lected adipokines (adiponectin, leptin and fatty ac-
id binding protein 4 (FABP4)). The postprandial 
responses of free fatty acids (FFAs), triglycerides 
(TG), glucose, insulin, as well as glucose-depen-
dent insulinotropic peptide (GIP) were measured.
Material and Methods
Characteristics of Patients
The study was approved by the Ethics Commit-
tee of the Jagiellonian University Collegium Med-
icum (No. KBET/52/B/2008). Written informed 
consent was obtained from all study participants. 
HIV infected, ARV-naive patients were re-
cruited from Outpatient Clinic of the University 
Hospital in Krakow. Patients with active oppor-
tunistic infections, neoplastic diseases, HCV and 
HBV coinfection, metabolic complications, body 
mass index (BMI) ≥ 25, as well as those smoking 
cigarettes and taking any other medications were 
excluded from the study. All patients at the mo-
ment of the enrollment into the study required 
the introduction of ARV drugs, and were quali-
fied to the therapy according the HIV guidelines, 
on the basis of the provider doctor decision (Ta-
ble 1). Only patients who, based on the provider 
decision, were offered therapy with regimen con-
taining two nucleoside reverse transcriptase in-
hibitors (NRTIs) combined with one protease 
inhibitor (PI) regimen were included into the in-
vestigation. Overall 13 patients were recruited into 
the study, 11 (85%) men and 2 women (15%), aged 
30.5 years (min. 23, max. 42). The following com-
binations of NRTIs were used in investigated pa-
tients: tenofovir/emtricitabine – 7 pts, tenofovir/ 
/lamivudine – 3 pts, abacavir/lamivudine – 3 pts. 
All PIs used in the study were boosted by ritonavir 
(r): 6 patients were treated with atazanvir/r, 5 with 
darunavir/r and 2 with lopinavir/r. Detailed char-
acteristics of patients are presented in Table 1. 
The study was conducted for 12 months, and the 
blood was collected after 6 months, as well as after 
12 months of above therapy. To monitor the ther-
apy CD4 cell count and viral load were measured 
according to HIV guidelines. In all investigated 
patients, accordant immunological and virologi-
cal response to the therapy was achieved (Table 1). 
None of the patients interrupted or changed their 
therapy during the observation period, but two 
of them refused to participate in the study after 
6 months. 
Body Composition Assessment
Assessment of patients body composition, in-
cluding: Body Fat Content (Body Fat % (B. FAT%), 
body fat mass (B.FAT kg)), body mass index 
(BMI), body impedance, resting metabolic rate 
(RMR), lean mass weight (Lean Kg), lean mass % 
(Lean %) was determined by Maltron BF-907 Ana-
lyzer. The anthropometric measurements, includ-
ing: waist to hip ratio were performed. During the 
follow-up, patients were asked to fill in a self-as-
sessment questionnaire regarding changes in their 
body composition. 
To assess more accurate changes in the fat dis-
tribution connected with ARV therapy adipose tis-
sue volume of abdomen and thighs was measured 
by CT examination and abdomen/thighs fat vol-
ume ratio was calculated. A CT scan was done at 
the moment of the enrollment into the study as 
well as 6 and 12 months later. 
CT examinations were performed using a helical 
16-row scanner Siemens Somatom Sensation 16.
After obtaining a lateral topogram of the ab-
domen, scanning of a single slice 10 mm thick at 
the level of the lower edge of L4 vertebral body was 
performed (voltage 120 kV, current 170 mA, re-
construction kernel B31s) – Fig. 1.
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After obtaining an anterio-posterior topogram 
of thighs, a single slice 10 mm thick shaft center 
at the level of the right femur was scanned (volt-
age 120 kV, current 170 mA, reconstruction kernel 
B31s) – Fig. 2. Two axial scans were imported into 
3D Slicer v. 4.1 (http://www.slicer.org) program1 
in DICOM format. Independently for both the 
above-mentioned images, the pixels representing 
Table 1. Patients characteristic
HIV infected- before 
ARV therapy (n-13)
HIV infected – 
6 months after 
introduction of ARV 
therapy (n-13)
HIV- infected 12 mo 
after introduction of 
ARV therapy (n-11)
Friedman’s Test
CD4 cells/μL 301 (± 78.2,  
min. 148 – max. 383)
477.20 (± 162.22, 
min. 199–max. 696)
565 (± 163.40,  
min. 249–max. 802) 
Chi-square – 20.462
p < 0.001
Viral load copii/mL 278 351 (min. 5 700–
max. 1 3100)
206.6 (± 376.9, min. 
34–max. 1440)




Body Mass Index 
(BMI)
24 24.15 24.80 Chi-square – 0.194
ns.
Waist to Hip ratio 
(WHR)
0.89 (± 0.076, min. 
0.75–max. 0.99)
0.92 (± 0.08, min. 
0.81–max. 1.08)
0.92 (± 0.63, min. 
0.80–max. 1.08)
Chi-square – 3.073 
ns.
Body Fat (BFAT kg) 16.58 (± 5.96, min. 
8.9–max. 26.2)
16.2 (± 6.21, min. 
9–max. 29.9)




Impedance 519.384 (± 64.9, min. 
426–max. 622)
501.5 (± 64.2, min. 
373–max. 583)






1751.5 (± 171.5, min. 
1466.0–max. 2089.0)
1769, 6 (± 171. 4, 
min. 1475–max. 2054)




CT adipose tissue 
volume at abdomen 
level [mm3]
230553.77  
(± 87517.67, min. 
98925–max. 362616)
254847.92  
(± 76139.82, min. 
146532–max. 405397)
247620.73  




 CT adipose tissue 
volume at thigh 
level [mm3]
111490.31  
(± 63629.25, min. 
58498–max. 266838)
125494.08  
(± 64191.25, min. 
75703–max. 301495)
124495.27  




CT ratio of adipose 
tissue volume at 
abdomen/thigh 
[mm3]
2.27 (± 0.79, min. 
1.28–max. 3.54)
2.24 (± 0.80, min. 
1.34–max. 3.58)




ns. – non significant.
Fig. 1. CT – slice at the level of the lower edge of L4 
vertebral body
Fig. 2. CT – slice at the level of the right femur shaft 
center
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the table for the patient were manually removed 
in the program from the measurement region. 
Next, an automatic segmentation of body regions 
with adipose tissue attenuation was performed, as-
suming the range of values from –150 to –30 HU 
– Fig. 3. Finally, the program calculated volumes 
of the above-mentioned regions. The values ob-
tained were documented as absolute numbers: ad-
ipose tissue volume in a slice at the level of abdo-
men [mm3], adipose tissue volume in a slice at the 
level of thighs [mm3] and ratio of these values [9].
Laboratory Analysis
CD4 cells count was analyzed by a flow cytom-
eter and HIV-1 load was determined by the HIV 
Cobas Ampliprep CAP-CTM-HIV using the Co-
bas Ampilcor system (Roche Diagnostic). 
Changes in lipid profile (fasting lipidogram (to-
tal cholesterol (TC), low-density lipoprotein (LDL), 
triglycerides (TG), high-density lipoprotein (HDL) 
were tested before ARV therapy was introduced, as 
well as 6 and 12 months thereafter. In addition, an 
oral lipid tolerance test (OLTT) was performed ac-
cording to Tanaka et al. [10]. Baseline blood sam-
ples were collected after 10 hours overnight fasting 
to assess fasting: triglycerides (TG), free fatty acids 
(FFAs), glucose, insulin, incretin (GIP) levels, and 
then patients ingested a high-fat breakfast. Venous 
blood samples were collected after 2 and 4 h, for re-
testing the above-mentioned parameters. 
Fasting plasma glucose, total cholesterol (TC), 
triglycerides (TG), low-density lipoprotein (LDL), 
high-density lipoprotein (HDL) were estimated by 
usual enzymatic procedures. FFAs were measured 
in non-frozen plasma by enzymatic colorimetric 
method (Roche Applied Science). Fasting insulin 
level was measured by immunoradiometric meth-
od (Diasource Immunoassys) and read-out us-
ing the gamma counter LKB Instruments. Method 
sensitivity was 1 μIU/mL, precision within the as-
say 2.1% and inter assay precision 6.5%. 
Insulin resistance index (HOMA-IR) was cal-
culated on the basis of the following formula: HO-
MA-IR = fasting insulin μU/mL) x fasting plasma 
glucose (mmol/l)/22.5. HOMA-IR above > 2.5 was 
considered to define insulin resistance. 
Fasting GIP concentration was measured us-
ing ELISA kit (Millipore Corporation, accuracy, 
86.7 ± 3%, precision: inter assay 1.8–6.1% and in-
ter assay 3.0–8.8%).
To assess TNFα, IL-6, adiponectin, leptin and 
FABP4 concentrations, 0.5 mL of serum was im-
mediately frozen and stored up to 12 months at 
–80oC. Serum levels of TNFα and IL-6 were mea-
sured by high sensitivity ELISA tests (R&D Sys-
tem) according to manufacturer protocol with sen-
sitivity 0.12 pg/mL, 0.04 pg/mL respectively, and 
precision within the assay was expressed as coef-
ficient of variation (CV) around 6% and 7%. Inter 
assay precision was around 10%, and 8%.
To assess serum leptin and adiponectin (hu-
man total adiponectin/Acrp30) immunoenzymat-
ic assays (R&D System) with sensitivity 7.8 pg/mL 
and 0.25 ng/mL respectively were used. CV was 
3% and 4%, and inter assay precision around 4% 
and 6%.
FABP4 concentration was evaluated by immu-
noenzymatic method (BioVendor), with a sensi-
tivity of 0.05 ng/mL, CV around 2.5%, and inter 
assay precision around 4%.
Statistical Analysis
The results are shown as mean ± standard de-
viation (SD). The comparisons between investigat-
ed groups were performed using the Anova Fried-
man’s test. To carry out a pairwise comparison, 
a post hoc analysis for the Friedman’s test was done 
for two related samples. To measure the oral lip-
id tolerance (OLTT) test, the area under the curves 
(AUCs) were calculated by the trapezoidal rule. 
Correlations were assessed using the Pearson test 
and r coefficients were shown. p-value < 0.05 was 
considered as statistically significant. Analysis of the 
results was carried out using the SPSS version 21. 
Results 
Metabolic Changes During  
the 12 Months Follow-up Study
During the 12 months of the follow-up, we did 
not observe clinically explicit lipodystrophy in in-
vestigated HIV infected patients, and there were no 
Fig. 3. CT – slice at the level of the lower edge of L4 
vertebral body with adipose tissue segmentation
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statistically significant changes in waist to hip ratio 
(WHR), as well as the ratio of adipose tissue volume 
in a slice at the level of the abdomen [mm3] to ad-
ipose tissue volume in a slice at the level of thighs 
[mm3] (Table 1). The tendency (Chi-square –5.538, 
p = 0.063) of adipose tissue volume in a slice of the 
thigh to increase was observed during this period 
(Table 1). There was an increase of adipose tissue 
volume at the level of the thigh after 6 months of 
ART as compared with the baseline (p < 0.05). Pa-
tients (n = 3), who in the self-assessment question-
naire reported changes in body composition, had an 
increase of ratio of adipose tissue volume at abdo-
men to thigh level at the 12th month. 
The CT adipose tissue volume at abdomen lev-
el [mm3] at the baseline, 6 and 12 months positive-
ly correlated with leptin level (r = 0.7368, p < 0.01 
vs. r = 0.6711, p < 0.05 vs. r = 0.7142, p < 0.05). 
There was also a positive correlation with FABP4 
at month 6th and 12th of the follow-up (r = 0.5534, 
p < 0.05 vs. r = 0.7024, p < 0.05).
The adipose tissue volume at the abdomen level 
[mm3] measured by CT at month 12th positively cor-
related with the total cholesterol (TC) (r = 0.7238, 
p < 0.05), insulin level (r = 0.6568, p < 0.05) and 
HOMA-IR (r = 0.7219, p < 0.05). Also, adipose tis-
sue volume at thigh level [mm3] measured by CT 
during the whole period of the follow-up positively 
correlated with leptin level (r = 0.9423, p < 0.001vs. 
r = 0.7362, p < 0.01 vs. r = 0.8899, p < 0.001). 
CT ratio of adipose tissue volume at abdomen/
thigh [mm3] positively correlated with FFAs level 
(r = 0.6826, p < 0.05) at baseline and with insulin 
level (r = 0.8781, p < 0.001), HOMA-IR (r = 0.9043, 
p < 0.001) and FABP4 concentration (r = 0.7515, 
p < 0.001) after the 12 months of observation.
There was a negative correlation of the chang-
es of adipose tissue volume at thigh level [mm3] (12 
months minus baseline) with the LDL (r = –0.7471, 
p < 0.01) (Fig. 4.) and a positive correlation with 
TG level (r = 0.6791, p < 0.05). We have not ob-
served changes in BMI, body fat composition 
(BFAT kg) and RMR (Table 1.), though body fat 
mass measured by impedance method was lower 
after 12 months as compared with the baseline and 
after 6 months of ART (p < 0.05). 
There were no changes in the lipid profile of 
investigated patients before the introduction of 
ARV therapy, although 6 months later 4 (31%) of 
them developed dyslipidemia; 1 (8%) had mixed 
dyslipidemia and 3 (23%) of the patients had an el-
evated triglycerides level (> 2.2 mmol/l). 
The similar pattern of metabolic changes was 
observed 12 months after the introduction of thera-
py. There were statistically significant changes in TC 
and TG concentrations in the investigated patients 
during the follow-up, as compared with baseline val-
ues. Detailed characteristics of changes in lipid pro-
file during the study were presented in Table 2. 
The performed analysis reveals a significantly 
higher TG level after 12 months of therapy as com-
pared with TG at the moment of the recruitment 
into the study (p < 0.05). 
Before the ARV therapy was introduced, 3 pa-
tients (23%) had insulin resistance (IR), 6 months 
later 5 patients (38.5%) had HOMA-IR > 2.5 as 
compared with 3 (27%) patients at month 12th. 
There were no differences in IR, as well as in 
glucose and insulin concentration during the 12 
months of the follow-up (Table 2). 
Fasting and postprandial glucose, insulin, GIP, 
FFAs, TG concentrations at baseline and 6 and 12 
months after the introduction of ART are present-
ed in Table 3. 
Statistically significant changes in fasting FFAs 
concentrations were observed during the follow-up 
(p < 0.05) (Table 4). The performed analysis con-
firmed statistically higher fasting FFAs 12 months 
after the introduction of ARV therapy, as com-
pared with fasting FFAs at baseline (p < 0.05). Not 
Fig. 4. Correlation of adipose tissue volume 
at thigh level with LDL-cholesterol after 
12 months of therapy. Negative correla-
tion of adipose tissue volume at thigh level 
[mm3] (12 months minus baseline) with 
LDL-cholesterol level after 12 months of 
ARV therapy (r = –0.7471, p < 0.01)
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Table 2. Metabolic changes during the 12 months of ARV therapy 
Before introduction 
of ARV therapy – 0
6 months after 
introduction – I
12 months after 
introduction – II
Friedman’s test
Total Cholesterol (TC) 
mmol/l
4.04 (± 0.7, min. 
3.21–max. 5.1)
4.78 (± 0.54, min. 
3.84–max. 5.7)






2.82 (± 0.6, min. 
0.6–max. 3.1) 
2.56 (± 0.44, min. 
1.92–max. 3.4)






1.14 (± 0.2, min. 
0.8–max. 1.4)
1.33 (± 0.31, min. 
0.96–max. 2.0)






1.21 (± 0.40, min. 
0.19–max. 1.4)
1.85 (± 0.68, min. 
0.8–max. 3.6)




Free fatty acids (FFAs) 
mmol/l
0.71 (± 0.41, min. 
0.19–max. 5.6)
0.65 (± 0.31, min. 
0.23–max. 1.38)




Fasting glucose  
mmol/mL
4.83 (± 0.37, min. 
4.2–max. 5.6)
4.98(± 0.89, min. 
4.0–max.6.2)




Insulin μU/mL 9.44 (± 3.14, min. 
6.1–max. 17.9)
13.22 (± 9.16, min. 
6.6–max. 39.2)




HOMA-IR 2.03 (± 0.73, min. 
1.27–max. 3.90)
3.11 (± 2.88, min. 
1.35–max. 12.2)




Data are presented as mean (± SD, minimum–maximum).
Table 3. Changes in cytokines and adipokines concentrations during the 12 months of ARV therapy
Before introduction  
of ARV therapy – 0
6 months after  
introduction – I
12 months after  
introduction – II
Friedman’s test
TNFα pg/mL 2.89 (± 1.88,  
min. 1.05–max.12.44)
1.46 (± 0.62,  
min. 90–max. 3.37)




IL-6 pg/mL 1.85 (± 1.83,  
min. 0.52–max. 7.55)
1.09 (± 0.44,  
min. 0.60–max. 2.11)






6.84 (± 3.13,  
min. 1.6–max. 11. 57)
7.72 (± 4.25,  
min. 1.86–max. 16.85)




Leptin ng/mL 3.78 (± 5.30,  
min. 0.26–max. 17.01)
4.64 (± 5.41,  
min. 0.63–max. 19.35)




FABP4 ng/mL 16.90 (± 6.26,  
min. 7.1–max. 25.12)
16.69 (± 5.49)  
min. 7.58–max. 28.97)




Data are presented as mean (± SD, min–max).
only fasting, but also postprandial level of FFAs was 
found to increase during the follow-up, which was 
manifested by increased plasma FFAs concentra-
tions 2 hours after the OLTT (p < 0.05) (Table 4), 
as well as by increased AUC for FFAs changes dur-
ing OLTT after 12 month of the therapy as com-
pared with baseline (Fig. 5). 
Regarding other investigated parameters (glu-
cose, insulin, GIP), there were no statistically signifi-
cant differences in oral lipid tolerance test during the 
12 months of observation (Table 4). The level of TG 
2 hours after the meal was higher at month 6th and 
12th, as compared with levels before introduction of 
ARV drugs (p < 0.05, p < 0.01). Postprandial response 
of TG, assessed as AUC increased after 6 months of 
the therapy, and then remained on a similar level to 
the end of observation (Fig. 6). Total insulin AUC 
was increased 6 months after the ARV drugs were 
introduced, and the same tendency was observed for 
HOMA-IR. Any significant changes (only tendency 
to increased release during OLTT) in GIP concentra-
tion were found in the course of ARV therapy.
Concerning proinflammatory cytokines, we ob-
served a statistically significant decrease of the TNFα, 
as IL-6 plasma levels had a tendency to decrease 
(p = 0.1) (Table 2). The performed tests revealed 
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that TNFα after the 6 months of ART was signifi-
cantly lower than at the baseline (p < 0.01), as well as 
after the 12 months and baseline (p < 0.01). Fasting 
concentrations of leptin had a tendency to increase 
(p = 0.1) during the 12 months of ART (Table 2). 
Analysis of leptin concentrations elicited that differ-
ences in concentration were observed mainly dur-
ing the first 6 months of therapy (p = 0.09). 
We did not notice any significant changes in 
adiponectin or FABP4 protein during the period 
of the study.  
Discussion
As life of HIV infected patients is prolonged 
because of effective ARV therapy, the frequency 
of metabolic disorders is increasing and may have 
a significant impact on their survival [8, 11]. 
Taking the above into consideration we de-
signed the follow-up study to assess the signs of 
metabolic disorders development, as well as in-
flammation connected with infection and en-
docrine function of adipose tissue in the group 
Table 4. Changes in oral lipid tolerance test (OLTT) results during 12 months of ARV therapy 
Before introduction  
of ARV therapy – 0
6 months after  
introduction – I





4.83 (± 0.37,  
min. 4.2–max. 5.6)
4.98 (± 0.89,  
min. 4.0–max. 6.2)
4.65 (± 0.47,  
min. 4.3–max. 5.4)




4.67 (± 0.65,  
min. 3.6–max. 6.3)
4.75 (± 0.91,  
min. 3.6–max. 6.9)
4.43 (± 0.58,  
min. 3.5–max. 5.6)




4.88 (± min. 4.4– 
max. 6.2)
5.23 (± 0.64,  
min. 4.1–max. 6.2)
4.74 (± 0.47,  
min. 3.9–max. 5.6)




9.44 (± 3.14,  
min. 6.1–max. 17.9)
13.22 (± 9.16,  
min. 6.6–max. 39.2)
10.24 (± 6.27,  
min. 5.6–max. 20.7)




19.59 (± 8.0,  
min. 9.3–max. 36)
24.91 (± 15.73,  
min. 7.8–max. 54.6)
21.69 (± 7.88,  
min. 12.2–max. 31.8)




10.40 (± 3.24,  
min. 6.3–max. 17.6)
14.06 (± 8.49,  
min. 7.6–max. 31.5)
12.24 (± 8.57,  
min. 12.2–max. 31.8)




80.88 (± 40.06, min. 
33.65–max. 164.99)
101.58 (± 80.24, min. 
11.33–max. 342.42)
93.78 (± 63.07, min. 
34.57–max. 252.77)




491.05 (± 143.8, min. 
262.23–max. 720.78)
419.9 (± 189.6, min. 
199.11–max. 934.55)






264.34 (± 98.61, min. 
129.82–max. 428.79)
346.9 (± 157.8, min. 
148–max. 737.87)






1.27 (± 0.40,  
min. 0.19–max. 1.4)
1.85 (±0.68,  
min. 0.8–max. 3.6)






1.73 (± 0.43, 
min. 1.01–max. 2.5)
2.42 (± 1.06,  
min. 1.44–max. 4.85)






1.88 (± 0.83,  
min. 0.96–max. 3.54)
2.43 (± 1.21,  
min. 1.33–5.28)






0.71 (± 0.41,  
min. 0.19–max. 5.6)
0.65 (± 0.31,  
min. 0.23–max. 1.38)






0.38 (± 0.26,  
min. 01–max.1.11)
0.51 (± 0.25,  
min. 0.21–max. 0.99)






0.59 (± 0.26,  
min. 0.35–max. 1.05)
0.61(± 0.27,  
min. 0.23–max. 1.22)




Data are presented as mean (± SD, minimum–maximum). 
0 – baseline blood samples collected after 10 hours overnight fast, to assess fasting triglycerides (TG), free fatty acids (FFAs), 
glucose, insulin, incretin (GIP) levels.
2 – retesting the above mentioned parameters from the blood samples collected 2 hours after fatty meal ingestion. 4 – retest-
ing the above mentioned parameters from the blood samples collected 4 hours after fatty meal ingestion.
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of HIV infected people under the PIs-based 
therapy. 
Conducted assessment of the body com-
position and fat distribution using a CT scan 
quantification did not reveal significant chang-
es of adipose tissue volume during the period of 
12 months as measured at abdominal and thigh 
level. It confirms clinical observations that mod-
ern ARV therapy less frequently causes overt li-
podystrophy [11, 12]. However, in our study we 
observed that adipose tissue volume at thigh lev-
el measured by CT significantly increased during 
the first 6 months of the follow-up. Also, Calmy 
et al. reported the increase of the limb fat mass af-
ter 6 months of ARV therapy, although from week 
24 there was a progressive loss of limb adipose tis-
sue [13]. It must be stressed that in contrast to our 
protocol, in the above study patients were treat-
ed either with non-nucleoside reverse transcrip-
tase inhibitor (NRTI) efavirenz or protease inhib-
itor (PI) nelfinavir, which is currently withdrawn 
from therapy. Also, a significant impact on their 
result had the fact that the backbone of ARV was 
the combination of NRTIs which are strongly 
linked with lipoatrophy development (didanosine 
and stavudine) [14]. 
In our study the adipose tissue volume at thigh 
level measured by CT, positively correlated with 
the increase of leptin concentrations. Similar ob-
servations were also previously reported in non-
HIV infected obese patients [15]. Gluteofemoral 
adipose tissue is suggested to have special associa-
tions with metabolic health. The fat accumulation 
in this region can protect against insulin resistance, 
diabetes mellitus and cardiovascular diseases [16]. 
Whereas leptin is considered to be the marker of li-
podystrophy in HIV infected patients [17, 18]. The 
relationship between the muscle fat infiltration de-
rived from CT scans and metabolic syndrome in 
postmenopausal women were explored, and its 
correlation with the development of metabolic dis-
turbances disorders was suggested [19]. Thus, our 
study, as well as the Calmy et al., can suggest that 
leptin and limb fat percentage independently pre-
dict the selective loss of limb fat and may occur as 
soon as from week 24 onwards [13]. Therefore, in 
spite of the lack of clinical symptoms of lipodystro-
phy, the changes in CT ratio of adipose tissue vol-
ume at abdomen/thigh during the follow-up point 
to the development of metabolic abnormalities.
ARV drugs administration resulted with the 
development of dyslipidemia. Triglycerides levels 
Fig. 5. Effect of duration of ARV 
PI-based therapy on postprandial 
free fatty acids (FFAs) concentra-
tions. Incremental Area Under the 
Curves (AUCs) for FFAs during the 
oral lipid loading test (OLTT). 
* p < 0.05 12 months ARV treatment 
vs. before therapy
Fig. 6. Effect of duration of ARV 
PI-based therapy on postprandial 
triglycerides (TG) concentrations.  
Incremental Area Under the Curves 
(AUCs) for TG during the oral 
lipid loading test (OLLT). *p < 0.05 
6 months ARV treatment vs. before 
therapy. 
* p < 0.05 12 months ARV treatment 
vs. before therapy
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significantly increased during the first 12 months, 
which was reported also by other investigators 
[20]. These observations are also supported by an-
imal models, which proved that the administra-
tion of PI, ritonavir to mice increases levels of TG, 
FFAs and TC. Histopathological analysis docu-
mented that PIs-based therapy led to the inflam-
mation of epidymal fat and increased the level of 
proinflammatory mediators [21]. 
In our study we also observed a delayed post-
prandial clearance of TG, which can be considered 
as an independent risk factor for cardiovascular 
diseases [22]. As adipose tissue is in large extent re-
sponsible for FFA/TG clearance on the basis of the 
above data, it can be concluded that this capacity of 
adipocytes is impaired by ARV therapy [23]. 
 We proved that ARV therapy leads to an in-
crease of fasting, as well as postprandial FFAs. It 
shows that HIV infected individuals, even without 
obvious lipodystrophy, experienced increased li-
polysis, as well as they can have impaired adipocyte 
FFAs trapping. These changes in FFAs concentra-
tion can be a triggering event for the development 
of other metabolic complications, as hypertriglyc-
eridemia and insulin resistance [24]. FFAs reach-
ing the liver may up-regulate the production of 
TG, which will partially explain the observations 
mentioned above [25]. It is suggested that the oxi-
dation rate of plasma FFAs remains unaltered and 
non-oxidative fatty acid disposal may be increased 
by reesterification in the liver [26]. Augmented in-
trahepatic FFAs availability contributes to the in-
creased very low-density lipoprotein (VLDL)-tri-
glyceride secretion rate, resulting in increase of 
TG concentration [26, 27]. Increased FFAs plasma 
concentrations lead to fat accumulation in differ-
ent organs and subsequently to insulin resistance 
[26]. We did not observe in our study any signifi-
cant increases of HOMA-IR, only a tendency, but 
this can be due to the short period of observation. 
There is also data about a potential positive impact 
of reducing the adipocyte size and lowering plasma 
FFAs. PPAR-γ, which is expressed predominantly 
in adipose tissue, plays crucial roles in regulating 
adipocyte differentiation, fatty acid metabolism. 
Yang et al. suggested that a reduction in adipo-
cyte size and an increase in FFAs uptake in the ad-
ipose tissue were partly attributed to upregulation 
of PPAR-γ and its target genes [28]. Lack of chang-
es in the protective adiponectin, and an increase in 
leptin may add to the marker of these unwanted ef-
fects. In contrast to other investigators, we did not 
observe changes in the concentration of FABP4 
during the one year of ARV therapy, which may 
suggest that changes in leptin concentration is the 
better predictor of possible upcoming changes in 
fat distribution and metabolic disturbances [29]. 
As reported, the ARV therapy decreases the level 
of proinflammatory cytokines: TNFα and IL-6 at 
month 12 of the follow-up [4, 13].
The changes in insulin secretion was not relat-
ed to the postprandial GIP secretion, since any sig-
nificant changes were observed during the whole 
period of the study, independently if HIV infected 
patients were drug naive or ARV treated. 
The above observations indicate that thera-
peutic interventions against increased blood FFAs 
levels can be beneficial in HIV infected ARV treat-
ed patients. It is suggested that PPAR-γ agonist 
rosiglitazone can decrease fasting FFAs levels in 
HIV individuals, although it has not been effect-
ing postprandial FFAs concentrations [30]. Our 
study has some limitations connected mainly with 
the small sample size, so the results must be inter-
preted with caution. Although we have decided to 
publish the initial results of the presented study, as 
to our knowledge it is the first follow-up study on 
metabolic disturbances and endocrine function of 
adipose tissue in which patients were treated only 
with modern PIs with exclusion of NRTIs. 
The authors have confirmed a significant im-
pact of ARV therapy on metabolic disorders. One 
year ARV therapy reduces inflammation measured 
by TNFα and IL-6 blood concentrations. Adipose 
tissue remodeling associated with the increased 
blood concentration of FFAs, indicating lipotox-
icity, as well as impaired adipocyte FFAs trapping 
is a triggering event in the development of hyper-
triglyceridemia during the course of ARV therapy. 
Changes in postprandial FFAs and TG indicate the 
increasing risk of cardiovascular diseases during 
the ARV therapy. We conclude also that modern 
ARV therapy during the period of 12 months does 
not induce significant changes in the total body 
fat content. Nevertheless fat redistribution corre-
lated with higher leptin level, pointing to the in-
creased risk of cardiovascular complications devel-
oping. Due to the small number of patients, results 
must be interpreted with caution and this sugges-
tion needs further studies.
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